Hi

MindBio is pleased to report on long term stability data for its lead candidate drug MB22001. These stability findings, are an important part of our commercialisation journey, to produce medicines that can be stored and used safely for long periods at home by patients suffering from mental health conditions.

See news release below:

MINDBIO DEVELOPS LONG TERM SHELF-STABLE MICRODOSING FORMULATION AND IS PROGRESSING IN MULTIPLE PHASE 2B CLINICAL TRIALS

Vancouver, British Columbia – October 8, 2024 – MindBio Therapeutics Corp. (CSE: MBIO); (Frankfurt: WF6), (the “Company” or “MindBio”), a leading biopharmaceutical company in psychiatric medicine development using microdoses of psychedelic medicines, is delighted to report its microdosing formulation MB22001 has achieved shelf stability at room temperature for 12 months.

MB22001 is a proprietary and self-titratable form of Lysergic Acid Diethylamide (LSD) which has been formulated for safe, take-home use by patients suffering from depression and is currently being trialed in patients at home. The stability data for MB22001 is significant in MindBio’s quest to make psychedelic medicines readily available in the form of microdoses for take home use. The Company’s investment and scientific thesis is that small, take home microdoses is the most scalable way to use psychedelic medicines to treat mental health conditions. 

The microdoses are sub hallucinogenic and have a profound impact on mood and subjective feelings of well-being, energy and happiness and once taken, patients can get on with their day.

Ensuring an adequate shelf life is a critical component for regulatory compliance and ease of use by patients. Having validated 12 months of shelf life in normal conditions, MindBio is able to guarantee that MB22001 remains safe and effective for patients during this period and will continue to assess stability of the medicine as time progresses. Stability testing helps uphold product quality and protect patient safety which are key regulatory requirements.  

MB22001 is being tested vigorously, now in multiple Phase 2B clinical trials. Previously released data from a Phase 2A depression trial reported improvements in MADRS Score (Montgomery-Asberg Depression Rating Scale) indicating an overall 60% decrease in depressive symptoms at the end of the treatment period and a 53% complete remission from depression.  

The Company has reported a sustained antidepressant response of MB22001 at 1 months and 3 months post treatment cycle. The Company looks forward to revealing 6 month post treatment data from its Phase 2A trial shortly.

Data from prior trials also indicates improvements in a range of secondary outcome measures following an 8-week treatment course with MB22001. This includes a 52% reduction in anxiety (HAM-A), and self-reported reductions in stress (35%), anxiety (59%) and depression (40%) using the DASS questionnaire. Participant’s psychological quality of life was improved by 37% as measured by the WHOQOL.  

Safety analysis has shown a favorable adverse event profile with a low frequency of adverse events with no serious or severe adverse events recorded. No clinically significant abnormalities were seen in follow up blood tests, electrocardiograms or echocardiograms.

Justin Hanka, Chief Executive Officer of MindBio said, “We are satisfied that MB22001 is shaping up to be a medicine with much promise for treating patients suffering from Major Depressive Disorder and this stability data is confirmatory that we have a commercially viable product for safe, long term home storage”.  

We invite you to join us in support of creating a brighter future for mental health.

Stay Well!

JUSTIN HANKA

Chief Executive Officer & Co-Founder

MindBio Therapeutics Corp (Frankfurt: WF6), (CNSX: MBIO)

Follow CEO Justin Hanka on LinkedIn:

https://www.linkedin.com/in/justinhanka/

Follow MindBio on LinkedIn: https://www.linkedin.com/company/mindbio-therapeutics/?viewAsMember=true